The Pennant Group (NASDAQ:PNTG) Raised to Buy at Wall Street Zen

The Pennant Group (NASDAQ:PNTG) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Several other brokerages have also weighed in on PNTG. Jefferies Financial Group assumed coverage on The Pennant Group in a research report on Friday, October 24th. They issued a “buy” rating and a $30.00 price objective for the company. Truist Financial decreased their price target on The Pennant Group from $32.00 to $28.00 and set a “hold” rating on the stock in a research note on Wednesday, July 16th. Stephens restated an “overweight” rating and set a $40.00 price target on shares of The Pennant Group in a research report on Thursday, October 9th. Wells Fargo & Company cut their price objective on The Pennant Group from $31.00 to $29.00 and set an “equal weight” rating on the stock in a report on Thursday, August 14th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of The Pennant Group in a research note on Wednesday. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, The Pennant Group presently has a consensus rating of “Hold” and an average target price of $31.75.

The Pennant Group Trading Up 7.5%

Shares of PNTG stock opened at $25.54 on Friday. The company has a current ratio of 1.04, a quick ratio of 1.21 and a debt-to-equity ratio of 0.08. The Pennant Group has a twelve month low of $21.18 and a twelve month high of $34.27. The company’s 50-day moving average price is $24.77 and its 200-day moving average price is $25.82. The stock has a market cap of $883.43 million, a price-to-earnings ratio of 34.05, a PEG ratio of 1.95 and a beta of 1.39.

The Pennant Group (NASDAQ:PNTG) last issued its earnings results on Wednesday, November 5th. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.29 by $0.01. The company had revenue of $229.04 million for the quarter, compared to the consensus estimate of $221.96 million. The Pennant Group had a net margin of 3.15% and a return on equity of 9.37%. The Pennant Group has set its FY 2025 guidance at 1.140-1.180 EPS. As a group, equities analysts predict that The Pennant Group will post 0.75 earnings per share for the current year.

Institutional Investors Weigh In On The Pennant Group

A number of large investors have recently modified their holdings of the company. Van Berkom & Associates Inc. lifted its position in shares of The Pennant Group by 10.1% during the 3rd quarter. Van Berkom & Associates Inc. now owns 3,112,812 shares of the company’s stock worth $78,505,000 after purchasing an additional 284,856 shares during the last quarter. 8 Knots Management LLC raised its stake in The Pennant Group by 23.9% in the first quarter. 8 Knots Management LLC now owns 3,014,023 shares of the company’s stock valued at $75,803,000 after buying an additional 581,313 shares in the last quarter. Ophir Asset Management Pty Ltd lifted its holdings in The Pennant Group by 403.9% during the 2nd quarter. Ophir Asset Management Pty Ltd now owns 1,048,759 shares of the company’s stock worth $31,305,000 after buying an additional 840,642 shares during the last quarter. Paradigm Capital Management Inc. NY lifted its holdings in The Pennant Group by 1.7% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 955,000 shares of the company’s stock worth $24,018,000 after buying an additional 16,000 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of The Pennant Group by 4.6% during the 2nd quarter. Geode Capital Management LLC now owns 832,481 shares of the company’s stock worth $24,853,000 after acquiring an additional 36,357 shares in the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

About The Pennant Group

The Pennant Group, Inc provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families.